Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases

Compounds having the general formula (I)

• wherein
• R1 is selected from the group comprising:
• —H, linear or branched substituted or unsubstituted C1-C6 alkyl, linear or branched C2-C6 alkenyl or linear or branched C2-C6 alkinyl;
• R2 and R4 are independently selected from the group consisting of:
• —H, linear or branched substituted or unsubstituted C1-C6 alkyl, linear or branched C2-C6 alkenyl, linear or branched C2-C6 alkinyl, aryl, —F, —Cl, —Br, —I, —CN, —NH2 or —NO2;
• R3 is selected from the group comprising:
• —F, —Cl, —Br, —I, substituted or unsubstituted aryl, substituted or unsubstituted —O—aryl, —NH-aryl, —S-aryl, or substituted or unsubstituted —O-heterocyclyl, —NH-heterocyclyl, —S-heterocyclyl, or substituted or unsubstituted —CH═CH-aryl, or substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocyclyl, or substituted or unsubstituted C3-C8 cycloalkyl, or —NH—(CH2)n—X, wherein n is an integer from 0 to 6 and X is selected from —OH, —NH2 or substituted or unsubstituted C3-C8 cycloalkyl;
• R5 is selected from the group consisting of:
• substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted C3-C8 cycloalkyl, or —(CH2)o—Y, wherein o is an integer from 0 to 6 and Y represents substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl or substituted or unsubstituted C3-C8 cycloalkyl;
• R6 is selected from the group consisting of:
• —H, linear or branched substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl, substituted pyrrolidinyl, substituted or unsubstituted C3-C8 cycloalkyl, disubstituted cyclohexyl, cyclopentyl, substituted or unsubstituted C5-C12 bicycloalkyl, substituted or unsubstituted adamantyl, —(CH2)q-group, wherein q is an integer from 1 to 3, under the proviso, if R6 is selected to be a methylene chain —(CH2)q-group, R17 or R19 are selected to be a methylene chain —(CH2)s-group, wherein s is an integer from 1 to 3 or a —(CH2)t-A-group, t is an integer from 1 to 3 and A is selected from O or N, respectively, and R6 and R17 or R6 and R19 form together a 5 to 8 membered ring system,
• or R6 represents —(CH2)p-Z, wherein p is an integer from 0 to 6 and Z is selected from the group comprising:
• substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl, —N(R7R8), wherein R7 and R8 represent independently from each other —H, or linear or branched substituted or unsubstituted C1-C6 alkyl, or Z is selected from —(CR9R10R11), wherein R9, R10 and R11 are independently of each other selected from the group consisting of:
• —H, linear or branched substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted aryl or —N(R12R13), wherein R12 and R13 represent independently of each other —H or linear or branched substituted or unsubstituted C1-C6 alkyl,
• under the proviso, if Z represents —(CR9R10R11) as defined above, p is selected to be an integer from 0 to 6, and
• if Z is selected from substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl, or —N(R7R8) as defined above, p is selected to be an integer from 1 to 6;
• L is selected from the group comprising:
• —NR14—SO2—, —NR14—SO—,
• wherein R14 is selected from —H, linear or branched substituted or unsubstituted C1-C6 alkyl, —SO2—R15 or —R15—SO2—, wherein R15 is selected from linear or branched substituted or unsubstituted C1-C6 alkyl or C1-C6 alkylen, or R14 represents —(CH2)r-COOR16, wherein r is an integer from 0 to 6 and R16 is selected from —H or linear or branched substituted or unsubstituted C1-C6 alkyl,
• —NR17—CO—,
• wherein R17 is selected from —H, linear or branched substituted or unsubstituted C1-C6 alkyl, or a —(CH2)s-group, wherein s is an integer from 1 to 3, and
• wherein R6 and R17 represent both a methylene chain group, R6 and R17 may form together a 5 to 8 membered ring system:
• —SO2—NR18—,
• wherein R18 is selected from —H, or linear or branched substituted or unsubstituted C1-C6 alkyl,
• —CO—NR19—,
• wherein R19 is selected from —H, linear or branched substituted or unsubstituted C1-C6 alkyl, or a —(CH2)t-A- group, wherein t is an integer from 1 to 3 and A is selected from N or O, and wherein if R6 represents a —(CH2)q-group and R19 represents a —(CH2)t-A- group, R6 and R19 may form together a 5 to 8 membered ring system
• and m is selected to be 0 or 1,
• and/or stereoisomeric forms and/or pharmaceutically acceptable salts thereof.